MedTrace Logo

Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients

NCT00901264 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2012-11-14

No results posted yet for this study

Summary

The purpose of this study is to correlate the results of the MICK assay with short- and long-term results of treatments in cancer patients and evaluate the role of the MiCK assay in guiding chemotherapy of cancer patients.

Conditions

Sponsors & Collaborators

  • Pierian Biosciences

    lead INDUSTRY

Principal Investigators

  • Cary Presant, MD · Pierian Biosciences

  • Dirk Davidson, MD · Cumberland Medical Center

  • Karl Rogers, MD · Nashville Oncology Associates

  • Swapnil P. Rajurkar, MD · Wilshire Oncology Medical Group, Inc.

  • Laura Lawson, MD · Tennessee Breast Specialists

  • L. James Wudel Jr., MD · Tennessee Thoracic Surgical Specialists

  • Raymond F Bluth, MD · Baptist Hospital Nashville

  • Peter F Jelsma, MD · St. Thomas Research Institute, LLC

  • Richard D Michaelson, MD · Middle Tennessee Medical Center

  • Jorge E Marcet, MD · Tampa Gerneral Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00901264 on ClinicalTrials.gov